Loading
Takara Bio Inc. is a listed company. Filings by its managers are published through EDINET (Japan FSA). In the past year (18 October 2025 to 18 October 2026), 3 filings came from 2 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
With 3 filings in twelve months, the company is in line with the median of 3 filings across the 3,419 companies we follow on the same exchange.
Over the last twelve months, not one insider purchase of Takara Bio Inc. stock was filed. The median gap between a trade and its publication by EDINET (Japan FSA) is 6 days. Until a filing is published, the market cannot know about the trade.
Every figure here comes from the filings published by EDINET (Japan FSA) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
3 of 3 declarations
Takara Bio Inc. is a Japanese biotechnology company that provides products and services in research and development. It is listed on the Tokyo Stock Exchange under the symbol XTKS.